

MSD and NHS in collaboration:

Working together to support the NHS in pathway implementation and optimisation



NHS hospital trusts are currently facing a number of challenges in oncology departments, affecting parts of the patient pathway, from referral through to treatment

What’s causing these challenges?



Increasing number of patients compared with current demand¹



New treatments becoming available²



Staff shortage³



Impact of COVID-19 pandemic⁴

How can MSD help?

At MSD we understand this and have a dedicated team who can work with you to optimise and implement pathways, tailored to any challenges you may be facing in your hospital, to improve care and management for your patients.

MSD can help optimise and implement pathways within your NHS trust through the Pathway Development Programme (PDP)

The MSD PDP is conducted under a collaborative working agreement which aims to support NHS organisations and healthcare professionals in delivering improved care and management for their patients.

How does the programme work?



STEP 1 - MSD’s dedicated team will work with you to understand the current service pathway and the demands on the health service



STEP 2 - The team will help to identify gaps in the current pathway, and highlight potential areas to improve – and the risks involved with not optimising these areas



STEP 3 - The MSD team will facilitate conversations about the changes needed for service improvements



STEP 4 - MSD will support in the implementation and evaluation of the service improvement, and then publish the outcomes



To find out more about our PDPs, visit our site by scanning this QR code or clicking here: [Collaborative Working - MSD UK](#)
This is an MSD website intended for UK healthcare professionals only. Alternatively, please contact a member of the MSD healthcare team at: msdukhealthcare@msd.com.

This material was produced and funded by MSD UK and it is intended for healthcare professionals only.
COVID-19, coronavirus disease 2019; NHS, National Health Service; PDP, pathway development programme.

- References**
1. NHS Providers. Understanding cancer performance in the NHS. Available at: <https://nhsproviders.org/news-blogs/blogs/understanding-cancer-performance-in-the-nhs>. Accessed April 2023.
 2. Navigating Cancer. The Emerging Challenges in Cancer Care. Available at: www.navigatingcancer.com/the-emerging-challenges-in-cancer-care. Accessed April 2023.
 3. Ham C. *BMJ* 2021;375:2587.
 4. Riera R, et al. *JCO Global Oncology* 2021;(7):311–323.

Confidentiality and disclosures
The pathways are constructed by a member of the MSD oncology team* in collaboration with a member of the NHS using data provided by the NHS. The pathway documents, gap analysis and business case/service development plans (if applicable) reflect specific practice and therefore may not be indicative of current guidelines and local/national policies. There is no patient interaction or identification throughout the process. A Transfer of Value (ToV) declaration will be made for the signing NHS organisation, based on the total hours spent to complete the piece of work.

*A member of the Oncology Team refers to an Oncology Healthcare Lead, Implementation Lead, Area Healthcare Lead, Key account manager and/or relevant MSD representative.

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. GB-NON-07249 | August 2023

